JP7441002B2 - リポソーム製剤のためのｐ－エトキシ核酸 - Google Patents

リポソーム製剤のためのｐ－エトキシ核酸 Download PDF

Info

Publication number
JP7441002B2
JP7441002B2 JP2018539236A JP2018539236A JP7441002B2 JP 7441002 B2 JP7441002 B2 JP 7441002B2 JP 2018539236 A JP2018539236 A JP 2018539236A JP 2018539236 A JP2018539236 A JP 2018539236A JP 7441002 B2 JP7441002 B2 JP 7441002B2
Authority
JP
Japan
Prior art keywords
composition
oligonucleotides
oligonucleotide
therapy
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018539236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018534361A5 (cg-RX-API-DMAC7.html
JP2018534361A (ja
Inventor
ピーター ニールセン，
Original Assignee
バイオ－パス ホールディングス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオ－パス ホールディングス， インコーポレイテッド filed Critical バイオ－パス ホールディングス， インコーポレイテッド
Publication of JP2018534361A publication Critical patent/JP2018534361A/ja
Publication of JP2018534361A5 publication Critical patent/JP2018534361A5/ja
Priority to JP2021205957A priority Critical patent/JP2022027993A/ja
Application granted granted Critical
Publication of JP7441002B2 publication Critical patent/JP7441002B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
JP2018539236A 2015-10-14 2016-10-14 リポソーム製剤のためのｐ－エトキシ核酸 Active JP7441002B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021205957A JP2022027993A (ja) 2015-10-14 2021-12-20 リポソーム製剤のためのｐ－エトキシ核酸

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562241503P 2015-10-14 2015-10-14
US62/241,503 2015-10-14
PCT/US2016/057148 WO2017066643A1 (en) 2015-10-14 2016-10-14 P-ethoxy nucleic acids for liposomal formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021205957A Division JP2022027993A (ja) 2015-10-14 2021-12-20 リポソーム製剤のためのｐ－エトキシ核酸

Publications (3)

Publication Number Publication Date
JP2018534361A JP2018534361A (ja) 2018-11-22
JP2018534361A5 JP2018534361A5 (cg-RX-API-DMAC7.html) 2019-11-21
JP7441002B2 true JP7441002B2 (ja) 2024-02-29

Family

ID=57209904

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018539236A Active JP7441002B2 (ja) 2015-10-14 2016-10-14 リポソーム製剤のためのｐ－エトキシ核酸
JP2021205957A Withdrawn JP2022027993A (ja) 2015-10-14 2021-12-20 リポソーム製剤のためのｐ－エトキシ核酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021205957A Withdrawn JP2022027993A (ja) 2015-10-14 2021-12-20 リポソーム製剤のためのｐ－エトキシ核酸

Country Status (13)

Country Link
US (5) US9744187B2 (cg-RX-API-DMAC7.html)
EP (1) EP3362563A1 (cg-RX-API-DMAC7.html)
JP (2) JP7441002B2 (cg-RX-API-DMAC7.html)
KR (1) KR102755601B1 (cg-RX-API-DMAC7.html)
CN (1) CN108291227A (cg-RX-API-DMAC7.html)
AU (1) AU2016340123B2 (cg-RX-API-DMAC7.html)
CO (1) CO2018004821A2 (cg-RX-API-DMAC7.html)
EA (1) EA038277B1 (cg-RX-API-DMAC7.html)
HK (1) HK1258370A1 (cg-RX-API-DMAC7.html)
IL (1) IL258625B2 (cg-RX-API-DMAC7.html)
MX (1) MX2018004637A (cg-RX-API-DMAC7.html)
SG (2) SG11201802718PA (cg-RX-API-DMAC7.html)
WO (1) WO2017066643A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108260357A (zh) 2015-04-10 2018-07-06 托马斯杰弗逊大学 用于通过选择性减少免疫调节m2单核细胞治疗癌症及增强治疗性免疫力的方法和组合物
US9744187B2 (en) 2015-10-14 2017-08-29 Bio-Path Holdings, Inc. p-Ethoxy nucleic acids for liposomal formulation
AU2017325971A1 (en) 2016-09-16 2019-04-11 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
EP4378531A3 (en) 2017-03-09 2024-09-04 Thomas Jefferson University Methods and compositions for treating cancers using antisense
US20200038429A1 (en) 2017-04-19 2020-02-06 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for igf-1r inhibition
EP3612160A4 (en) 2017-04-19 2021-01-20 Bio-Path Holdings, Inc. P-ETHOXY NUCLEIC ACIDS TO INHIBIT BCL2
SG11201909336VA (en) * 2017-04-19 2019-11-28 Bio Path Holdings Inc P-ethoxy nucleic acids for stat3 inhibition
CN110650727A (zh) * 2017-04-19 2020-01-03 拜奥-帕斯控股股份有限公司 用于igf-1r抑制的p-乙氧基核酸
CN112204140A (zh) 2018-01-24 2021-01-08 托马斯杰弗逊大学 生物扩散室

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015886A (en) 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
JP2001502172A (ja) 1996-10-04 2001-02-20 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム リポソームアンチセンスオリゴデオキシヌクレオチドによるＢｃｌ―２タンパク質発現の阻害
JP2003511405A (ja) 1999-10-08 2003-03-25 アルザ・コーポレーション 核酸および薬剤送達用の中性−カチオン性脂質
JP2010531820A (ja) 2007-06-29 2010-09-30 スタテンス セールム インスティトゥート モノミコリルグリセロール（ｍｍｇ）のアジュバントとしての使用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187702B1 (en) 1985-01-07 1990-03-14 Syntex (U.S.A.) Inc. N-(omega,omega-1-dialkoxy)- and n-(omega,omega-1-dialkenoxy)-alk-1-yl-n,n,n-trisubstituted ammonium surfactants, their preparation and pharmaceutical formulations containing them
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5087617A (en) 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5248671A (en) 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5708154A (en) 1989-02-24 1998-01-13 City Of Hope RNA-DNA hybrid molecules of nucleic acid
JPH05504552A (ja) 1989-10-24 1993-07-15 ギリアド　サイエンシズ，インコーポレイテッド ２’位が改変されたオリゴヌクレオチド
US5872232A (en) 1990-01-11 1999-02-16 Isis Pharmaceuticals Inc. 2'-O-modified oligonucleotides
US5859221A (en) 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5614617A (en) 1990-07-27 1997-03-25 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
US5223618A (en) 1990-08-13 1993-06-29 Isis Pharmaceuticals, Inc. 4'-desmethyl nucleoside analog compounds
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US6111094A (en) * 1990-08-14 2000-08-29 Isis Pharmaceuticals Inc. Enhanced antisense modulation of ICAM-1
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
DK51092D0 (da) 1991-05-24 1992-04-15 Ole Buchardt Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5766855A (en) 1991-05-24 1998-06-16 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity and sequence specificity
US5525719A (en) * 1991-08-30 1996-06-11 Chemgenes Corporation N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
EP0628051B1 (en) 1992-02-12 2003-07-02 Chromagen, Inc. Applications of fluorescent n-nucleosides and fluorescent structural analogs of n-nucleosides
US5652099A (en) 1992-02-12 1997-07-29 Conrad; Michael J. Probes comprising fluorescent nucleosides and uses thereof
GB9211979D0 (en) 1992-06-05 1992-07-15 Buchard Ole Uses of nucleic acid analogues
US5438131A (en) 1992-09-16 1995-08-01 Bergstrom; Donald E. 3-nitropyrrole nucleoside
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5858988A (en) 1993-02-24 1999-01-12 Wang; Jui H. Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
WO1995012387A1 (en) 1993-11-05 1995-05-11 Amgen Inc. Liposome preparation and material encapsulation method
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US5670663A (en) 1996-02-14 1997-09-23 Regents Of The University Of California Recovery of taxanes from conifers
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US7309692B1 (en) 1996-07-08 2007-12-18 Board Of Regents, The University Of Texas System Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
US5886165A (en) 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5908845A (en) 1996-10-30 1999-06-01 Segev; David Polyether nucleic acids
US7262173B2 (en) 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US7704962B1 (en) * 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6274725B1 (en) * 1998-06-02 2001-08-14 Isis Pharmaceuticals, Inc. Activators for oligonucleotide synthesis
US20030180789A1 (en) 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
JP4688294B2 (ja) 1998-12-30 2011-05-25 オリゴス・イーティーシー・インコーポレイテッド 酸安定性骨格で修飾された末端がブロックされた核酸及びその治療的使用
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US20050186264A1 (en) * 2000-10-12 2005-08-25 Kiani Mohammad F. Targeting drug/gene carriers to irradiated tissue
WO2002057480A2 (en) * 2001-01-22 2002-07-25 Genta Incorporated Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers
US7425545B2 (en) * 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
JP4491240B2 (ja) * 2002-01-17 2010-06-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア Ｉｇｆｂｐ−２およびｉｇｆｂｐ−５を阻害する二重特異性アンチセンスオリゴヌクレオチド、並びにこれらの使用方法
US20030147813A1 (en) 2002-02-07 2003-08-07 John Lyons Method for treating chronic myelogenous leukemia
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
EP2314691A3 (en) 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
EP1737980A2 (en) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
EP1931782B2 (en) * 2005-08-29 2016-04-20 Regulus Therapeutics Inc Methods for use in modulating mir-122a
US20070190382A1 (en) 2006-02-10 2007-08-16 Fischer Bernhard A Hydrocarbon reformer system
US7915399B2 (en) 2006-06-09 2011-03-29 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US20080171718A1 (en) * 2006-11-08 2008-07-17 Brown Bob D Methods and Compositions for Treating Cancer Using BCL-2 Antisense Oligomers, Tyrosine Kinase Inhibitors, and Chemotherapeutic Agents
ES2530215T3 (es) 2007-11-06 2015-02-27 Adiutide Pharmaceuticals Gmbh Análogos de oligorribonucleótidos inmunoestimulantes que contienen restos de oligofosfato modificados
CA2736929C (en) 2008-10-02 2019-02-26 Life Sciences Research Partners Vzw Inhibition of plgf to treat philadelphia chromosome positive leukemia
US9289505B2 (en) 2010-08-17 2016-03-22 Rutgers, The State University Of New Jersey Compositions and methods for delivering nucleic acid molecules and treating cancer
AU2012217685B2 (en) 2011-02-15 2017-05-18 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
EP2683411B1 (en) * 2011-03-09 2016-01-13 The Brigham and Women's Hospital, Inc. Methods of using microrna-26a to promote angiogenesis
BR112013024768B1 (pt) 2011-04-01 2022-02-08 Ionis Pharmaceuticals, Inc Composto para inibição da expressão de mrna e proteína stat3, uso do composto e composição farmacêutica
EP3003275B1 (en) * 2013-06-03 2020-11-18 Bar-Ilan University Liposomes for modulating wiskott-aldrich syndrome protein
AU2014383024B2 (en) * 2013-12-03 2020-04-30 Exicure, Inc. Liposomal particles, methods of making same and uses thereof
CN108260357A (zh) 2015-04-10 2018-07-06 托马斯杰弗逊大学 用于通过选择性减少免疫调节m2单核细胞治疗癌症及增强治疗性免疫力的方法和组合物
US9744187B2 (en) 2015-10-14 2017-08-29 Bio-Path Holdings, Inc. p-Ethoxy nucleic acids for liposomal formulation
AU2017325971A1 (en) 2016-09-16 2019-04-11 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
EP4378531A3 (en) 2017-03-09 2024-09-04 Thomas Jefferson University Methods and compositions for treating cancers using antisense
CN110650727A (zh) 2017-04-19 2020-01-03 拜奥-帕斯控股股份有限公司 用于igf-1r抑制的p-乙氧基核酸
US20200038429A1 (en) 2017-04-19 2020-02-06 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for igf-1r inhibition
SG11201909336VA (en) 2017-04-19 2019-11-28 Bio Path Holdings Inc P-ethoxy nucleic acids for stat3 inhibition
EP3612160A4 (en) 2017-04-19 2021-01-20 Bio-Path Holdings, Inc. P-ETHOXY NUCLEIC ACIDS TO INHIBIT BCL2
MX2021011760A (es) 2019-03-28 2021-12-10 Univ Jefferson Metodos para el tratamiento de canceres usando antisentido.
CN112830354A (zh) 2019-11-22 2021-05-25 富泰华工业（深圳）有限公司 基于区块链系统的电梯调度系统、装置、方法及存储介质

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015886A (en) 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
JP2001502172A (ja) 1996-10-04 2001-02-20 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム リポソームアンチセンスオリゴデオキシヌクレオチドによるＢｃｌ―２タンパク質発現の阻害
JP2003511405A (ja) 1999-10-08 2003-03-25 アルザ・コーポレーション 核酸および薬剤送達用の中性−カチオン性脂質
JP2010531820A (ja) 2007-06-29 2010-09-30 スタテンス セールム インスティトゥート モノミコリルグリセロール（ｍｍｇ）のアジュバントとしての使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｆｏｒｍｕｌａｔｉｏｎ ｏｆ Ｌｉｐｏｆｅｃｔａｍｉｎｅ ２０００ ａｎｄ Ｌｉｐｏｆｅｃｔｉｎ， ＳｉｇｎａＧｅｎ Ｂｌｏｇ， ２０１５．０５．，＜ｈｔｔｐｓ：／／ｓｉｇｎａｇｅｎ．ｃｏｍ／ｂｌｏｇ／２０１５／１０／０５／ｆｏｒｍｕｌａｔｉｏｎ－ｏｆ－ｌｉｐｏｆｅｃｔａｍｉｎｅ－２０００－ａｎｄ－ｌｉｐｏｆｅｃｔｉｎ／＞
Ｐｒｏｃ． Ｎａｔｌ． Ａｃａｄ． Ｓｃｉ．， １９８９， Ｖｏｌ．８６， ｐｐ．６０７７－６０８１

Also Published As

Publication number Publication date
US20250255897A1 (en) 2025-08-14
KR102755601B1 (ko) 2025-01-17
CO2018004821A2 (es) 2018-11-22
US20170106010A1 (en) 2017-04-20
JP2022027993A (ja) 2022-02-14
US10898506B2 (en) 2021-01-26
AU2016340123B2 (en) 2022-09-22
US9744187B2 (en) 2017-08-29
MX2018004637A (es) 2019-05-06
NZ741793A (en) 2024-10-25
CN108291227A (zh) 2018-07-17
IL258625A (en) 2018-06-28
US10335428B2 (en) 2019-07-02
CA3001005A1 (en) 2017-04-20
IL258625B2 (en) 2025-02-01
US20200113928A1 (en) 2020-04-16
US20210361695A1 (en) 2021-11-25
WO2017066643A8 (en) 2018-05-03
EA038277B1 (ru) 2021-08-04
WO2017066643A1 (en) 2017-04-20
IL258625B1 (en) 2024-10-01
SG11201802718PA (en) 2018-05-30
HK1258370A1 (zh) 2019-11-08
EA201890940A1 (ru) 2018-10-31
JP2018534361A (ja) 2018-11-22
AU2016340123A1 (en) 2018-05-10
US20180161360A1 (en) 2018-06-14
KR20180091816A (ko) 2018-08-16
EP3362563A1 (en) 2018-08-22
SG10202104058XA (en) 2021-05-28
BR112018007611A2 (pt) 2018-10-23
US12097214B2 (en) 2024-09-24

Similar Documents

Publication Publication Date Title
JP7441002B2 (ja) リポソーム製剤のためのｐ－エトキシ核酸
US12319911B2 (en) P-ethoxy nucleic acids for STAT3 inhibition
WO2018195250A1 (en) P-ethoxy nucleic acids for igf-1r inhibition
JP2023052819A (ja) Ｂｃｌ２阻害のためのｐ－エトキシ核酸
JP2020517645A (ja) Ｉｇｆ−１ｒ阻害のためのｐ−エトキシ核酸
CA3058486C (en) P-ethoxy nucleic acids for bcl2 inhibition
CA3001005C (en) P-ethoxy nucleic acids for liposomal formulation
EA042663B1 (ru) Р-этокси нуклеиновые кислоты для ингибирования stat3
BR112018007611B1 (pt) Composição compreendendo oligonucleotídeos, composição farmacêutica compreendendo a dita composição, método in vitro para entregar o dito oligonucleotídeo a uma célula e uso da dita composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191010

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200812

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211220

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211220

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220105

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220303

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220304

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220401

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220405

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230308

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240216

R150 Certificate of patent or registration of utility model

Ref document number: 7441002

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150